Daily Policy Digest
|Know Your Plan: HSA vs. FSA
NCPA Senior Fellow Devon Herrick outlines the importance of knowing your health plan and ways to keep from leaving money on the table at the start of the New Year...
|The Doctor Will See You Now?
There is extensive evidence that telemedicine offers quality care on par with routine in-person visits, is well-received by patients and providers, and delivers considerable cost-savings...
|Don't Get Caught in the FSA Use-It-Or-Lose It Rush
Most employers place a December 31st deadline on spending funds in Flexible Spending Accounts, explains NCPA senior fellow Devon Herrick...
|Unpopular Individual Mandate Fails To Make People Buy Obamacare Coverage
The New York Times reports that a number of relatively high-income earners are choosing to remain uninsured, or even drop Obamacare coverage, and pay the fine instead...
|Patients are Becoming Price Sensitive but only Because Obamacare Destroyed Their Insurance
Paying for medical bills out of pocket is a problem because health care providers do not use prices to compete for the patronage of price-sensitive shoppers, writes NCPA Senior Fellow Devon Herrick...
|To Control Drug Prices, Pursue Fraud, Not Manufacturers
There is a better way to control escalating drug costs that by trying to control drug prices...
|Private Health Construction Leads Slow Building Market
In a turnaround from September, private health construction grew strongly, (0.6 percent) while public health construction starts collapsed -2.5 percent...
|Obamacare Beneficiaries' Bleak Future
As more insurers decide to quit, 10 million Obamacare subscribers will be left high and dry in short order, writes NCPA Senior Fellow John R. Graham in the Daily Caller...
|Health Services Spending Growing Faster Than Personal Consumption Expenditures
Obamacare is not bending the cost curve, writes NCPA Senior Fellow John R. Graham...
|Pharmaceutical Marketing, the FDA and Free Speech
The U.S. Justice Department and state attorneys general have repeatedly used the threat of prosecutions for drugmakers touting off-label uses of pharmaceuticals to wring billions of dollars in settlements, fines and civil damages from them.